Armata Pharmaceuticals
ARMP
14 hedge funds and large institutions have $486K invested in Armata Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more funds holding
Funds holding: 12 → 14 (+2)
2% more capital invested
Capital invested by funds: $475K → $486K (+$11K)
0.14% more ownership
Funds ownership: 1.19% → 1.32% (+0.14%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$88.9K |
| 2 |
Morgan Stanley
New York
|
+$8.2K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.96K |
| 4 |
Renaissance Technologies
New York
|
+$3.15K |
| 5 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$787 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$42K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.14K |
| 3 |
BlackRock
New York
|
-$2.38K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$279 |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $280K | +$3.15K | +800 | +1% |
|
|
2
Stifel Financial
St. Louis,
Missouri
| $84K | +$88.9K | +22,599 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $56K | -$4 | -1 | -0% |
|
|
4
BlackRock
New York
| $39K | -$2.38K | -605 | -5% |
|
5
Bank of Montreal
Toronto,
Ontario, Canada
| $9K | – | – | – |
|
|
6
Morgan Stanley
New York
| $8K | +$8.2K | +2,084 | +1,457% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $4K | +$3.96K | +1,007 | +3,596% |
|
|
8
UBS Group
Zurich,
Switzerland
| $2K | -$9.14K | -2,322 | -80% |
|
9
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $2K | – | – | – |
|
|
GWM
10
Geneos Wealth Management
Englewood,
Colorado
| $1K | -$279 | -71 | -14% |
|
|
TWA
11
TCI Wealth Advisors
Tucson,
Arizona
| $1K | +$787 | +200 | New |
|
|
PAM
12
Panagora Asset Management
Boston,
Massachusetts
| – | -$42K | -10,409 | Closed |
|
|
SFS
13
Sowell Financial Services
North Little Rock,
Arkansas
| – | +$429 | +109 | New |
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$433 | +110 | +220% |
|
ARMP Hedge Fund Activity: Q3 2019 in Review
14 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2019, worth a combined $486K — up 2.3% from $475K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ARMP positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Stifel Financial, opening a new position worth an estimated $88.9K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $42K sold.
- 14 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2019, up from 12 in Q2 2019.
- Funds reported $486K of Armata Pharmaceuticals stock for Q3 2019, up 2.3% quarter-over-quarter.
- 3 funds opened new Armata Pharmaceuticals positions in Q3 2019 and 1 closed out, a net change of +2 holders.
- The largest Armata Pharmaceuticals buyer in Q3 2019 was Stifel Financial, an estimated $88.9K added.
- The largest Armata Pharmaceuticals seller in Q3 2019 was Panagora Asset Management, an estimated $42K sold.
Based on aggregated 13F filings for Q3 2019.